New tool predicts survival in advanced prostate cancer

For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment. But a good prognostic tool has been lacking in this setting, particularly…

For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.

But a good prognostic tool has been lacking in this setting, particularly since a new chemotherapy called cabazitaxel as been approved by the U.S. Food and Drug Administration as another line of treatment.

Now researchers at the Duke Cancer Institute have developed a tool for doctors to forecast the potential survival of individual patients, enabling faster, more accurate information on whether to try additional rounds of treatment or seek clinical trials.

The findings are published online in the Journal of the National Cancer Institute.
“Our findings provide a prognostic tool that relies on information that is routinely collected in clinical practice and should be readily available,” said Susan Halabi, Ph.D., professor of biostatistics and bioinformatics at Duke and lead author of the study. “For patients with metastatic prostate cancer who are appropriate candidates for second-line chemotherapy, this model can be helpful for guiding care. It could also be used during clinical trials to assign patients in risk groups based on measurable criteria.”
In their study, Halabi and colleagues developed and validated the new prognostic tool using two different clinical trials of prostate cancer patients whose cancer returned after they had undergone a regimen of docetaxel, the standard first-round chemotherapy that is used after hormone treatments have been ineffective.
The researcher’s approach provides an understanding of the complex interactions between the host, the tumor factors and clinical outcomes.
By plugging in 17 variables — including pain intensity, measurable disease, race, age, body mass index and others — the researchers determined that certain key factors were relevant to overall survival.
Of the 17 variables, nine were determined to be predictive of survival: how a patient’s physical performance is rated on a scale of 0-2; the length of time since the first chemotherapy ended; how extensive the disease is; whether the disease has spread to the liver, lungs or other organs; how much pain the patient is experiencing; the duration of hormone use; and levels of hemoglobin, prostate specific antigen and alkaline phosphatase.
Two of those factors had not previously been used in prognostic models — the duration of hormone therapy and the amount of time since the first-round docetaxel treatment.
“Several new treatments have been developed in recent years that prolong life for men with metastatic prostate cancer,” Halabi said. “As a result, it’s increasingly important to provide a clear prognostic picture that can help guide both doctors and patients to the best options.”
This tool is available online at https://www.cancer.duke.edu/Nomogram/secondlinechemotheray.html

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is based on materials provided by Duke Medicine.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:
S. Halabi, C.-Y. Lin, E. J. Small, A. J. Armstrong, E. B. Kaplan, D. Petrylak, C. N. Sternberg, L. Shen, S. Oudard, J. de Bono, O. Sartor. Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. JNCI Journal of the National Cancer Institute, 2013; DOI: 10.1093/jnci/djt280

Note: If no author is given, the source is cited instead.

Search ScienceDaily
Number of stories in archives: 144,973

 

Interested in ad-free access? If you’d like to read ScienceDaily without ads, let us know!

more breaking science news

Social Networks
Follow ScienceDaily on Facebook, Twitter, and Google:

Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

Breaking News
… from NewsDaily.com

more science news
In Other News …
more top news
Science Video News

Heated Chemo
In efforts to boost the effectiveness of anti-cancer drugs, a new method called intra-peritoneal hyperthermic chemotherapy works by flushing a heated. …  > full story

Strange Science News
Free Subscriptions
… from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:
Email Newsletters
RSS Newsfeeds
Feedback
… we want to hear from you!

Tell us what you think of ScienceDaily — we welcome both positive and negative comments. Have any problems using the site? Questions?
Leave Feedback